Potential Drug Target and Biomarker for Neurological Disorders
Potential Drug Target and Biomarker for Neurological Disorders
OR52I1 (Olfactory Receptor OR11-13) is a protein that is expressed in the olfactory system, which is responsible for the sense of smell. OR52I1 has been identified as a potential drug target and a biomarker for various neurological and psychiatric disorders.
OR52I1 is a member of the Olfactory Receptor protein family, which consists of over 200 different proteins that are expressed in the olfactory system. These proteins are responsible for transmitting sensory information from the nose and brain to the rest of the body. OR52I1 is one of the proteins that is expressed in the olfactory system and is involved in the sense of smell.
Studies have shown that OR52I1 is involved in various physiological processes in the olfactory system, including the perception of odor, the identification of olfactory stimulation, and the regulation of olfactory sensitivity. OR52I1 has also been shown to be involved in the development and progression of various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia.
One of the potential reasons why OR52I1 is being targeted as a drug target is its involvement in the development and progression of Alzheimer's disease. Alzheimer's disease is a degenerative brain disorder that is characterized by the progressive loss of brain cells and the development of aggregates of the protein beta-amyloid. OR52I1 has been shown to be involved in the development and progression of beta-amyloid aggregates in the brains of individuals with Alzheimer's disease, and may be a potential drug target for the treatment of this disorder.
In addition to its involvement in the development and progression of Alzheimer's disease, OR52I1 has also been shown to be involved in the development and progression of other neurological and psychiatric disorders. For example, OR52I1 has been shown to be involved in the development and progression of Parkinson's disease, a neurological disorder characterized by the progressive loss of brain cells. Additionally, OR52I1 has been shown to be involved in the development and progression of schizophrenia, a psychiatric disorder characterized by the development of hallucinations and delusions.
Another potential reason why OR52I1 is being targeted as a drug target is its involvement in the regulation of olfactory sensitivity. Olfactory sensitivity is the ability of the olfactory system to detect and respond to different scents. OR52I1 has been shown to be involved in the regulation of olfactory sensitivity, and may be a potential drug target for the treatment of disorders that are characterized by reduced olfactory sensitivity.
In addition to its involvement in the regulation of olfactory sensitivity, OR52I1 has also been shown to be involved in the development and progression of various psychiatric disorders. For example, OR52I1 has been shown to be involved in the development and progression of depression, a psychiatric disorder characterized by the development of low mood and a reduced interest in activities. Additionally, OR52I1 has been shown to be involved in the development and progression of anxiety, a psychiatric disorder characterized by feelings of worry and apprehension.
In conclusion, OR52I1 is a protein that is expressed in the olfactory system and is involved in various physiological processes in this system. OR52I1 has also been shown to be involved in the development and progression of various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. As a result, OR52I1 is a potential drug target and a biomarker for these disorders. Further research is needed to fully understand the role of OR52I1 in these disorders and to develop effective treatments.
Protein Name: Olfactory Receptor Family 52 Subfamily I Member 1
Functions: Odorant receptor
The "OR52I1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR52I1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
OR52I2 | OR52J3 | OR52K1 | OR52K2 | OR52K3P | OR52L1 | OR52M1 | OR52N1 | OR52N4 | OR52N5 | OR52R1 | OR52W1 | OR52Z1P | OR56A1 | OR56A3 | OR56A4 | OR56A5 | OR56B1 | OR56B4 | OR5A1 | OR5A2 | OR5AC1 | OR5AC2 | OR5AK2 | OR5AK4P | OR5AN1 | OR5AP2 | OR5AR1 | OR5AS1 | OR5AU1 | OR5B12 | OR5B17 | OR5B2 | OR5B21 | OR5B3 | OR5BA1P | OR5C1 | OR5D13 | OR5D14 | OR5D16 | OR5D17P | OR5D18 | OR5E1P | OR5F1 | OR5H1 | OR5H14 | OR5H15 | OR5H2 | OR5H4P | OR5H6 | OR5I1 | OR5K1 | OR5K2 | OR5K3 | OR5K4 | OR5L1 | OR5L2 | OR5M1 | OR5M10 | OR5M11 | OR5M3 | OR5M4P | OR5M8 | OR5M9 | OR5P1P | OR5P2 | OR5P3 | OR5T1 | OR5T2 | OR5T3 | OR5V1 | OR5W2 | OR6A2 | OR6B1 | OR6B2 | OR6B3 | OR6C1 | OR6C2 | OR6C3 | OR6C4 | OR6C65 | OR6C70 | OR6C74 | OR6C75 | OR6C76 | OR6F1 | OR6J1 | OR6K2 | OR6K3 | OR6M1 | OR6N1 | OR6N2 | OR6P1 | OR6Q1 | OR6R2P | OR6S1 | OR6T1 | OR6W1P | OR6X1 | OR6Y1
